Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioNTech SE BNTX

Healthcare Biotechnology
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a... see more

Recent & Breaking News (NDAQ:BNTX)

BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

GlobeNewswire 4 days ago

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

GlobeNewswire April 7, 2024

BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

GlobeNewswire March 20, 2024

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

GlobeNewswire March 20, 2024

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsfile March 14, 2024

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsfile March 13, 2024

Levi & Korsinsky Reminds BioNTech Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 12, 2024 - BNTX

Accesswire March 12, 2024

BNTX DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX

PR Newswire March 12, 2024

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioNTech

Newsfile March 12, 2024

DEADLINE TODAY: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the Firm

Newsfile March 12, 2024

March 12, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BNTX

Accesswire March 12, 2024

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the Firm

Accesswire March 12, 2024

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsfile March 12, 2024

Class Action Filed Against BioNTech SE (BNTX) - March 12, 2024 Deadline to Join - Contact Levi & Korsinsky

PR Newswire March 12, 2024

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Accesswire March 12, 2024

BioNTech SE Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BNTX

Accesswire March 12, 2024

Shareholders of BioNTech SE Should Contact Levi & Korsinsky Before March 12, 2024 to Discuss Your Rights - BNTX

Accesswire March 12, 2024

FINAL BNTX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds BioNTech SE Investors to Join the Class Action Lawsuit!

Accesswire March 12, 2024

BioNTech SE Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 12, 2024 to Discuss Your Rights - BNTX

Accesswire March 11, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines - BNTX

PR Newswire March 11, 2024